Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Rating of “Buy” from Analysts

Annovis Bio, Inc. (NYSE:ANVS) has received a consensus rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $37.00.

Separately, D. Boral Capital reaffirmed a “hold” rating on shares of Annovis Bio in a research note on Monday, February 10th.

Annovis Bio Trading Down 3.4 %

Shares of NYSE:ANVS opened at $1.59 on Monday. The business has a 50-day moving average price of $1.61 and a 200 day moving average price of $4.52. Annovis Bio has a 12-month low of $1.11 and a 12-month high of $20.00. The company has a market capitalization of $22.56 million, a price-to-earnings ratio of -0.36 and a beta of 1.51.

Annovis Bio (NYSE:ANVS) last issued its quarterly earnings data on Friday, March 21st. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). During the same period in the previous year, the business posted ($0.43) EPS. As a group, equities research analysts predict that Annovis Bio will post -2.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Annovis Bio

Several large investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its stake in shares of Annovis Bio by 30.0% during the third quarter. Geode Capital Management LLC now owns 99,114 shares of the company’s stock worth $799,000 after buying an additional 22,881 shares during the period. Merit Financial Group LLC lifted its position in shares of Annovis Bio by 269.0% during the 4th quarter. Merit Financial Group LLC now owns 98,516 shares of the company’s stock worth $496,000 after purchasing an additional 71,816 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Annovis Bio by 99.7% during the fourth quarter. Jane Street Group LLC now owns 68,107 shares of the company’s stock worth $343,000 after purchasing an additional 34,001 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Annovis Bio in the fourth quarter valued at $258,000. Finally, State Street Corp raised its stake in Annovis Bio by 23.7% in the third quarter. State Street Corp now owns 36,035 shares of the company’s stock valued at $290,000 after buying an additional 6,900 shares in the last quarter. Hedge funds and other institutional investors own 15.83% of the company’s stock.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.